Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion
Mark Hatherill, MD
Abstract
The purpose of this study is to evaluate the safety and immunogenicity of ID93 + GLA-SE vaccine when administered to adult pulmonary Tuberculosis (TB) patients, following successful completion of TB treatment with confirmed bacteriologic cure, in preparation for a future Phase 2b prevention of TB recurrence trial in the same population.
MeSH terms
- Tuberculosis, Pulmonary
- Tuberculosis